首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

2126739

糖尿病疫苗市場：按年齡層、最終用戶和地區分類

Diabetes Vaccine Market, By Age Group (Up to 20 years of age and Above 20 years of age), By End User (Hospitals, Clinics, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

出版日期: 2026年08月10日 | 出版商:

Coherent Market Insights | 英文 257 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到2026年，糖尿病疫苗市場規模將達到8,960萬美元，到2033年將達到1.533億美元。預計從2026年到2033年，該市場將以8%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	8960萬美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	8.00%	2033年市場規模預測：	1.533億美元

由於人們越來越重視糖尿病的預防管理，免疫治療方法的研究和開發活動日益活躍，以及對創新緩解疾病療法的日益重視，糖尿病疫苗市場正在經歷轉型。糖尿病疫苗，包括治療性疫苗、免疫調節疫苗和抗原特異性疫苗，旨在調節免疫反應，同時應對疾病進展、長期管理挑戰和治療效果。該市場涵蓋第1型糖尿病的預防、第1型糖尿病的治療、自體免疫糖尿病的管理、兒童糖尿病、成人糖尿病、高風險族群篩檢以及臨床研究等領域的應用。

患者、研究人員和醫療保健專業人員正致力於採用先進的免疫策略來延緩疾病發作、改善患者預後並減少對傳統糖尿病管理方法的依賴。基於抗原的疫苗、免疫耐受技術和個人化治療方法的進步正在提高疫苗的有效性，尤其是在自體免疫糖尿病患者中。此外，精準醫療、生物標記識別和先進臨床試驗平台的日益普及，有助於最佳化疫苗研發和患者選擇，從而改善疾病管理效果並減輕糖尿病的長期負擔。

市場動態

由於人們對基於免疫的糖尿病療法的關注度不斷提高、疫苗研發投入增加以及對預防性和緩解疾病治療方法的需求日益成長，市場正經歷顯著成長。市場成長的主要驅動力來自生技公司、製藥開發商和研究機構，他們致力於尋求創新的疫苗平台，尤其針對自體免疫糖尿病高風險族群、新確診患者以及需要長期疾病預防策略的人。治療性疫苗、抗原特異性製劑、免疫耐受策略和個人化疫苗技術在糖尿病疫苗研發中發揮核心作用，有助於調節免疫反應、延緩疾病進展並改善治療效果。對早期療育、標靶治療和先進免疫解決方案的日益重視，正在推動糖尿病疫苗研發的需求。

精準醫療和免疫療法的發展正在推動市場成長。這主要得益於對自體免疫機制的深入理解、生物標記識別技術的進步以及針對糖尿病進展相關特定免疫路徑的候選疫苗的研發。包括免疫調節、細胞反應控制和個人化治療策略在內的創新方法，有助於改善治療效果並支持更有效的疾病管理。

對醫療保健解決方案和糖尿病替代管理策略日益成長的需求也在推動市場發展。醫療保健專業人員、內分泌學家、製藥公司、臨床研究人員和學術機構在推進臨床試驗和支持新型疫苗療法的引入方面發揮著至關重要的作用。隨著人們對糖尿病早期療育和下一代治療方案的認知不斷提高，預計市場將受益於研究經費的增加、監管的進步、臨床檢驗的改進以及更具針對性、安全性和有效性的糖尿病疫苗解決方案的推出。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數分析了糖尿病疫苗市場主要參與者的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本報告提供的見解將使行銷負責人和企業經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份「糖尿病疫苗市場」報告的目標受群眾外包括產業內的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
透過分析糖尿病疫苗市場時所使用的各種策略矩陣，相關人員將能夠做出更順利的決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第7章競爭情勢

熱圖分析
市佔率分析
公司簡介
- Diamyd Medical AB
- Vactech Oy
- Novo Nordisk A/S
- Imcyse SA
- COUR Pharmaceuticals Development Company, Inc.
- Precigen, Inc.-ActoBio Therapeutics
- Nova Immunotherapeutics Limited
- AnTolRx, Inc.
- AviSia Therapeutics BV
分析師意見

第8章

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI1367

Diabetes Vaccine Market is estimated to be valued at USD 89.6 Mn in 2026 and is expected to reach USD 153.3 Mn by 2033, growing at a compound annual growth rate (CAGR) of 8% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 89.6 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	8.00%	2033 Value Projection:	USD 153.3 Mn

The market is undergoing a transformation owing to the rising focus on preventive diabetes management, increasing research and development activities in immunotherapy approaches, and growing emphasis on innovative disease-modifying treatment solutions. Diabetes vaccines, including therapeutic vaccines, immune-modulating vaccines, and antigen-specific approaches, aim to regulate immune responses while addressing disease progression, long-term management challenges, and treatment outcomes. The market includes applications such as type 1 diabetes prevention, type 1 diabetes treatment, autoimmune diabetes management, pediatric diabetes, adult diabetes, high-risk population screening, and clinical research applications.

Patients, researchers, and healthcare providers are focusing on advanced immunological strategies to delay disease onset, improve patient outcomes, and reduce dependency on conventional diabetes management methods. The developments in antigen-based vaccines, immune tolerance technologies, and personalized therapeutic approaches are enhancing vaccine performance, especially among individuals with autoimmune-driven diabetes conditions. In addition, the growing use of precision medicine, biomarker identification, and advanced clinical trial platforms helps optimize vaccine development and patient selection, thereby supporting improved disease management outcomes and reducing the long-term burden of diabetes.

Market Dynamics

The market is witnessing significant advancements owing to the increasing focus on immune-based diabetes therapies, rising investments in vaccine research, and the growing need for preventive and disease-modifying treatment approaches. The market's growth is largely driven by biotechnology companies, pharmaceutical developers, and research institutions exploring innovative vaccine platforms, especially for individuals at risk of autoimmune diabetes, newly diagnosed patients, and populations requiring long-term disease prevention strategies. Therapeutic vaccines, antigen-specific formulations, immune tolerance approaches, and personalized vaccine technologies play a central role in diabetes vaccine development, thereby helping regulate immune responses, delay disease progression, and improve treatment outcomes. The rising emphasis on early intervention, targeted therapies, and advanced immunological solutions is strengthening the demand for diabetes vaccine research and development.

The expansion of precision medicine and immunotherapy-based approaches is fueling market growth. This is mainly driven by increasing understanding of autoimmune mechanisms, advancements in biomarker identification, and the development of vaccine candidates designed to target specific immune pathways associated with diabetes progression. Innovative approaches involving immune modulation, cellular response regulation, and personalized treatment strategies help improve therapeutic effectiveness and support better disease control.

The rising demand for preventive healthcare solutions and alternative diabetes management strategies is also propelling the market. Healthcare providers, endocrinologists, pharmaceutical companies, clinical researchers, and academic institutions play a crucial role in advancing clinical trials and supporting the adoption of emerging vaccine-based treatments. As awareness of early diabetes intervention and next-generation therapeutic options grows, the market is expected to benefit from increased research funding, regulatory advancements, improved clinical validation, and the introduction of more targeted, safe, and effective diabetes vaccine solutions.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Diabetes Vaccine Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Diamyd Medical AB, Vactech Oy, Novo Nordisk A/S, Imcyse SA, COUR Pharmaceuticals Development Company, Inc., Precigen, Inc., Nova Immunotherapeutics Limited, AnTolRx, Inc., AviSia Therapeutics B.V.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The Diabetes Vaccine Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Diabetes Vaccine Market

Market Segmentation

By Age Group (Revenue, USD Mn, 2021-2033)
Up to 20 years of age
Above 20 years of age
By End User (Revenue, USD Mn, 2021-2033)
Hospitals
Clinics
Others
By Region (Revenue, USD Mn, 2021-2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Key Players Insights
Diamyd Medical AB
Vactech Oy
Novo Nordisk A/S
Imcyse SA
COUR Pharmaceuticals Development Company, Inc.
Precigen, Inc. - ActoBio Therapeutics
Nova Immunotherapeutics Limited
AnTolRx, Inc.
AviSia Therapeutics B.V.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Age Group
- Market Snapshot, By End User
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Disease Type Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Global Diabetes Vaccine Market, By Age Group, 2021 - 2033, (USD Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Up to 20 years of age
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Above 20 years of age
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)

5. Global Diabetes Vaccine Market, By End User, 2021 - 2033, (USD Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)

6. Global Diabetes Vaccine Market, By Region, 2021 - 2033, (USD Million)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Million)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- Diamyd Medical AB
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Vactech Oy
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Novo Nordisk A/S
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Imcyse SA
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- COUR Pharmaceuticals Development Company, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Precigen, Inc. - ActoBio Therapeutics
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Nova Immunotherapeutics Limited
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- AnTolRx, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- AviSia Therapeutics B.V.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
Analyst Views